A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Table 5 Percentage change in IOP (mmHg) from baseline to week 4 (ANCOVA, PP population)

	Latanoprost concentration (μg/mL)
	50	75	100	125
N	69	66	71	68
Worse eye
8 a.m. IOP
LS mean change (mmHg)*	−37.6	−35.5	−37.3	−33.5
Difference in LS mean change ± SEM^‡		2.2 ± 1.7	0.3 ± 1.7	4.1 ± 1.7
(90% CI)		(−0.06, 5.0)	(−2.4, 3.1)	(1.3, 6.8)
p-value^‡		0.899	0.581	0.992
Study eye
8 a.m. IOP
LS mean change (mmHg)*	−37.2	−35.0	−36.4	−33.3
Difference in LS mean change ± SEM^‡		2.2 ± 1.7	0.8 ± 1.6	3.8 ± 1.6
(90% CI)		(−0.6, 4.9)	(−1.9, 3.4)	(1.1, 6.5)
p-value^‡		0.906	0.682	0.990

ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^‡Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^‡One-sided p-value.

ISSN: 1471-2415